HIV Clinical and Translational Research
Activities
The HIV Clinical and Translational Research (HIV-CTR) Group is interested in clinically oriented research in the field of resistance to antiviral therapy and transmission, as well as providing new translational knowledge on HIV cure and on HIV immunopathogenesis using humanized mouse models. The Group is a partner in several European HIV and HCV networks, collaborates with lifescience and biotech companies, and has built up a network in emerging countries (mainly in Africa) to support knowledge and technology transfer. The Group provides specialized technical support for the clinical follow-up of HIV and HCV-infected patients and is the first supplier of public health information for these infections in Luxembourg.
Collaborations:
- European Society for Translational Antiviral Research (ESAR) and the Hepvir working group for hepatitis B and C
- EURESIST
- Breach HIV Cure consortium
- the Monod consortium for the clinical trial NCT01127204, evaluation of simplified antiretroviral treatment strategies in HIV infected children treated by antiretroviral before one year of age
- the COST action CM1407, NatChemdrugs
Research projects
- HIV Molecular Epidemiology in Europe, the SPREAD surveillance program
- Toxicomania, hepatitis C and substitution: epidemiological, behavioral and clinical study in Luxembourg
- Development of heteromultimeric multifunctional therapeutic molecules activating the complement action towards target cells
- Assessment of the sequential events driving immune activation in the gut during acute HIV infection by using an in vivo model of humanized mice
- Challenging organic syntheses inspired by nature - from natural products chemistry to drug discovery
Featured Publications
Predominance of the heterozygous CCR5 delta-24 deletion in African individuals resistant to HIV infection might be related to a defect in CCR5 addressing at the cell surface.
- HIV Clinical and Translational Research
- Platform National Cytometry Platform
- Immuno-Pharmacology and Interactomics
- DII Custom Group 2
2019 Sep. J Int AIDS Soc.22(9):e25384.
FHR4-based immunoconjugates direct complement-dependent cytotoxicity and phagocytosis towards HER2-positive cancer cells.
- HIV Clinical and Translational Research
- Immuno-Pharmacology and Interactomics
- Platform National Cytometry Platform
2019 Jul. Mol Oncol. [Epub ahead of print].
